Jordana Joy

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold the Canada Health Act.

ZinserLab will focus on accelerating the development of imaging technologies in eye care.

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

The preservative-free, contact lens–friendly drops have been formulated to provide hydration and comfort for dry eyes in a multidose bottle.

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President Donald Trump under the International Emergency Economic Powers Act.

Lori Wright, JD, sat down to talk about a discussion at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

LUMIFY eye drops were initially introduced by Bausch + Lomb in 2018 and remain the only OTC redness relievers that selectively target eye redness with a lower risk of rebound redness and loss of efficacy when used as directed.

By making these retinal pigment epithelium (RPE) cells visible, researchers have created implications for early detection of disease and the monitoring of treatment response.

The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures such as laser treatments

LumiThera's Valeda system offers groundbreaking non-invasive treatment for dry AMD, showing extended vision improvement and safety over 4.5 years.

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.

Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.

The research team from the University of Cincinnati surveyed 42 patients 50 years of age and older at Hoxworth Eye Clinic

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with glaucoma with up to 5 years of follow up.

Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.

The affected mandate requires that all newborns receive erythromycin ointment applied to their eyes after birth, which helps prevent ophthalmia neonatorum.

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

The recall was conducted out of an abundance of caution after the company received reports of complications. The cause of said complications could not be immediately explained.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.